ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0244

Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients

James Cheng-Chung Wei1, Roy Fleischmann2, sarah Morris3, Vijay Hingorani4, Elizabeth Polvent5, Zancong Shen6, Shunqi Yan7, Li-Tain Yeh8 and Robert Keenan9, 1Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, 2Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 3Arthrosi Therapeutics Inc, San Diego, CA, 4Vanguard Healthsciences, Inc., San Diego, CA, 5Arthrosi Therapeutics, Inc., Roseville, CA, 6Arthrosi Therapeutics, San Diego, CA, 7Arthrosi Therapeutics, Inc., Laguna Hills, CA, 8Arthrosi Therapeutics, Inc., Irvine, CA, 9Arthrosi Therapeutics, Chapel Hill, NC

Meeting: ACR Convergence 2023

Keywords: clinical trial, gout, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized, double-blinded, 12-week, placebo-controlled phase 2b trial to evaluate the safety and efficacy of AR882 versus placebo in patients with gout. Here, we report the analysis of the efficacy and safety based on various demographics and baseline characteristics.

Methods: The trial recruited 140 gout patients 18 to 75 years of age with eGFR >30 mL/min across 20 sites in the US, Australia, and Taiwan. Subjects were recruited from the US (15 sites), Australia (2 sites) and Taiwan (3 sites), and were randomized into one of three treatment groups at a 1:1:1 ratio. Blood samples were collected every 2 weeks up to 12 weeks to monitor sUA levels and safety measures. Efficacy endpoints included the percent of patients who reached a sUA < 6, < 5 mg/dL and lower. Safety data, including vital signs and electrocardiograms, were collected throughout the study.

Results: Baseline characteristics of enrolled participants are illustrated in Table 1. The mean baseline sUA level was 8.6 (±1.3) mg/dL and was similar across regions (8.5-8.8 mg/dL), while mean body weights and BMI showed slight regional differences.

Common comorbidities in participants included hypertension, hyperlipidemia, chronic kidney disease, followed by arthritis, diabetes, and cardiovascular disease. The US population had a higher rate of comorbidities than those in Australia and Taiwan (Table 2).

In the intent-to-treat population, in the 75 mg group 82% and 73% of patients achieved sUA < 6 and < 5 mg/dL, respectively, and in the 50 mg group, 71% and 45% of patients achieved sUA levels < 6 and < 5 mg/dL, respectively. In the per-protocol population, in the 75 mg group 89% and 82% achieved sUA levels < 6 and < 5 mg/dL, respectively, and in the 50 mg group 78% and 50% achieved sUA levels < 6 and < 5 mg/dL, respectively. Patients in Australia and Taiwan showed slightly higher response rates than those in the US (Table 3), likely attributable to the difference in body weight and BMI. Patients with eGFR in the 60-89 mL/min range showed similar response rates to those with eGFR > 90 mL/min, and greater response rates than those with eGFR < 60 mL/min. There were no serious adverse events in AR882 treated patients. The most frequently reported adverse event was gout flare occurring in 30% of patients overall with similar distribution among placebo and AR882 treatment groups. Mild or moderate adverse events including diarrhea, headache, and upper respiratory infection were observed. None of the AEs led to discontinuation of investigational product.

Conclusion: 12-week treatment of AR882 demonstrated safe and efficacious profiles in gout patients with various demographics and baseline characteristics. AR882 may offer improved efficacy and better safety compared to existing therapies in the treatment of patients with gout including those with severe or refractory disease across various demographics and comorbidities.

Supporting image 1

Table 1.Demographics and baseline characteristics

Supporting image 2

Table 2. Patient comorbidities across regions

Supporting image 3

Table 3. Response rate of sUA lowering in patients across regions (per-protocol population)


Disclosures: J. Wei: Abbvie, 2, 5, 6, Amgen, 5, AstraZeneca, 6, BMS, 2, 5, 6, Celgene, 2, Chugai, 2, 6, Eisai, 2, 6, Eli Lilly, 2, 5, 6, Gilead, 5, GSK, 2, 5, Janssen, 2, 5, 6, Novartis, 2, 5, Pfizer, 2, 5, 6, Sanofi-Aventis, 2, SUN pharma, 5, TSH Taiwan, 2, UCB pharma, 2, 5; R. Fleischmann: AbbVie, 1, 2, 5, Amgen, 1, 2, 5, Bristol Myers Squibb, 1, 2, 5, Eli Lilly, 1, 2, 5, Galapagos, 1, 2, 5, Galvani, 1, 2, 5, Gilead, 1, 2, 5, GlaxoSmithKline, 1, 2, 5, Janssen, 1, 2, 5, Novartis, 1, 2, 5, Pfizer, 1, 2, 5, UCB, 1, 2, 5, Vyne, 1, 2, 5; s. Morris: Arthrosi Therapeutics, 3; V. Hingorani: None; E. Polvent: Arthrosi Therapeutics, 3; Z. Shen: Arthrosi therapeutics, 3; S. Yan: Arthrosi Therapeutics, 3; L. Yeh: Arthrosi Therapeutics, 3; R. Keenan: Arthrosi Therapeutics, 3.

To cite this abstract in AMA style:

Wei J, Fleischmann R, Morris s, Hingorani V, Polvent E, Shen Z, Yan S, Yeh L, Keenan R. Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-of-ar882-a-selective-uric-acid-transporter-1-urat1-inhibitor-in-gout-patients-with-various-baseline-characteristics-following-12-week-treatment-in-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-ar882-a-selective-uric-acid-transporter-1-urat1-inhibitor-in-gout-patients-with-various-baseline-characteristics-following-12-week-treatment-in-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology